München (ots) - Wenn es um den Einkauf von Luxuswaren wie Uhren und Schmuck geht, setzen Schweizer ...
MAQUET AND SWISSTOM GIVE NOTICE OF DISTRIBUTION PARTNERSHIP FOR WESTERN EUROPE
Rastatt, Landquart (ots) - MAQUET and Swisstom are pleased to announce their distribution partnership for the monitoring and diagnostic product Swisstom BB2.
Acute Lung Injury is still a leading cause of death for intensive care patients. Swisstom BB2 was especially developed to continuously monitor the lung function of ICU patients undergoing mechanical ventilation. It offers direct visualization of the lung aeration complementing high performant MAQUET SERVO ventilators, which have a long history in helping clinicians implementing protective ventilation strategies. Now the positive effects of Neurally Adjusted Ventilatory Assist (NAVA®) can be traced at the bedside with this real-time Electrical Impedance Tomography (EIT). This monitoring of ventilated patients is completely radiation-free. Therefore, Swisstom BB2 can be used continuously for several days.
"Understanding what really happens in the lungs during mechanical ventilation is still very challenging today", says Serge Exshaw, Vice President MAQUET Holding and Head of Global Sales and Marketing. MAQUET already developed tools including measured tidal volume per kilogram of predicted body weight in the new SERVO-U. "However seeing the lung aeration continuously and in real time represents a step further for individual adaptation to patient condition", he emphasizes. "We are really delighted about this partnership with Swisstom." MAQUET is one of the leading companies in critical care diagnostics and therapies. With its well-known brands like intensive care ventilators SERVO-i® or the new SERVO-U, and the Neurally Adjusted Ventilatory Assist (NAVA®), the company offers a wide range of therapeutic options to treat all patient categories including the sickest ones.
"Swisstom is proud to start a distribution partnership with MAQUET in Western Europe. The broad product portfolio and the excellent clinical knowhow of the MAQUET team combined with Swisstom's cutting edge technology will provide brand new solutions for hospitals", says Josef X. Brunner, Swisstom's CEO.
Swisstom AG, located in Landquart, Switzerland, develops and manufactures innovative medical devices. Swisstom creates its competitive edge by passionate leadership in non-invasive tomography with the goal to improve individual lives and therapies. For more information please visit www.swisstom.com or contact Dr. J. X. Brunner, CEO: email@example.com.
MAQUET, a trusted partner for hospitals and physicians for over 175 years, is the global leader in providing medical systems that meet the needs of the most medically challenging patients, while exceeding the expectations of the hospital teams that care for them. MAQUET designs, develops and distributes innovative therapy solutions and infrastructure capabilities for high-acuity areas within the hospital including the operating room (OR), hybrid OR / cath lab and intensive care unit (ICU) as well as intra and inter hospital patient transport.
Headquartered in Rastatt, Germany, MAQUET is the largest subsidiary of the publicly listed GETINGE Group AB of Sweden. MAQUET generated about 1.54 billion Euros in 2013, representing more than half of the Getinge Group's annual revenue of 2.9 billion Euros. MAQUET has 6,550 employees in over 45 international sales and service organizations, as well as a network of more than 300 sales partners. For more information please visit www.maquet.com.
MAQUET - The Gold Standard www.maquet.com www.getingegroup.com ##
MAQUET Vertrieb und Service Deutschland GmbH
VP Marketing Western Europe
Phone: +49 7222 932-914
MAQUET Holding B.V. & Co. KG
Manager Corporate Communications
Phone: +49 7222 932-1284